A practical reference on TB-500: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
== Enabling environment == According to the McKinsey Industry Digitization Index, the agricultural sector is the slowest adopter of digital technologies in the United States. Farm-level adoption of digital agriculture varies within and between countries, and uptake differs by technology. Some characterize precision agriculture uptake as rather slow. In the United States in 2010-2012, precision agriculture technologies were used on 30-50% of corn and soybean acreage. Others point out that uptake varies by technology; farmer use of GNSS guidance has grown rapidly, but variable-rate technology adoption rarely exceeds 20% of farms. Furthermore, digital agriculture is not limited to on-farm precision tools, and these innovations typically require less upfront investment. Growing access to ICTs in agriculture and a booming e-commerce market all bode well for increased adoption of digital agriculture downstream of the farm. Individual farmers' perceptions about usefulness, ease of use, and cost-effectiveness impact the spread of digital agriculture. In addition, a number of broader factors enable the spread of digital agriculture, including:
The gate formed by the α subunits prevents peptides longer than about four residues from entering the interior of the 20S particle. The ATP molecules bound before the initial recognition step are hydrolyzed before translocation. While energy is needed for substrate unfolding, it is not required for translocation. The assembled 26S proteasome can degrade unfolded proteins in the presence of a non-hydrolyzable ATP analog, but cannot degrade folded proteins, indicating that energy from ATP hydrolysis is used for substrate unfolding. Passage of the unfolded substrate through the opened gate occurs via facilitated diffusion if the 19S cap is in the ATP-bound state. The mechanism for unfolding of globular proteins is necessarily general, but somewhat dependent on the amino acid sequence. Long sequences of alternating glycine and alanine have been shown to inhibit substrate unfolding, decreasing the efficiency of proteasomal degradation; this results in the release of partially degraded byproducts, possibly due to the decoupling of the ATP hydrolysis and unfolding steps. Such glycine-alanine repeats are also found in nature, for example in silk fibroin; in particular, certain Epstein–Barr virus gene products bearing this sequence can stall the proteasome, helping the virus propagate by preventing antigen presentation on the major histocompatibility complex.
{\displaystyle {\text{eGFR}}={\text{170}}\ \times \ [{\text{Serum Creatinine}}]^{-0.999}\ \times \ {\text{Age}}^{-0.176}\ \times {\text{[0.762 if Female]}}\ \times {\text{[1.180 if Black]}}\ \times \ {\text{BUN}}^{-0.170}\ \times \ {\text{Albumin}}^{+0.318}}
Large language models (LLMs) are trained on tokenized text from large corpora and are capable of natural language processing, machine translation, and natural language generation. LLMs can be used as foundation models for a variety of downstream tasks. They can also be trained on source code to generate programs from prompts. Many applications combine large language models with external knowledge sources using retrieval-augmented generation (RAG), a technique in which relevant documents are retrieved at inference time and incorporated into the model's response. Generative AI has been integrated into content management and website publishing platforms, where large language models are used to generate text, assist with page composition, and automate website creation from natural language prompts. WordPress.com is one example of this application, incorporating generative AI into its website authoring workflow.
== Criteria == While proteomic methods identified many novel proteins that potentially might be adhesome components they cannot be regarded as adhesome components until they are validated to fulfill the following criteria: 1. they localize to a cell adhesion structure such as focal adhesion or adherens junction. 2. they directly interact with one of the core adhesome components, such as integrin, cadherin or catenins AND/OR their knockdown has a clear effect on cell adhesion.
Sources: en.wikipedia.org
Several critics complained about the required usage of the program Steam, the requirement to create an account, register the products, and permanently lock them to the account before being allowed to play, along with installation difficulties and lack of support.
==== Clean vehicle and clean energy home improvement tax credits eliminated ==== The tax credit for buying a new qualified electric vehicle or fuel cell electric vehicle is no longer available for purchases made after September 30, 2025. The tax credit for buying a used qualified electric vehicle or fuel cell vehicle from a licensed dealer is no longer available for purchases made after September 30, 2025. The tax credit for installing property to either recharge electric vehicles or to store or dispense clean-burning fuel will no longer be available after June 30, 2026. The tax credit for making qualified energy-efficient improvements to one's home will no longer be available for improvements put into service after December 31, 2025. The tax credit for installing solar electric panels, solar water heaters, wind turbines, geothermal heat pumps, fuel cells, or battery storage technology in one's home will no longer be available for improvements made after December 31, 2025.
Similarly, the number of one-year-olds fully immunised against measles rose from 30% in 1985–1990 to 40% in 2000–2005, and for tuberculosis, it grew nearly 20% from 31% to 50% over the same period. The number of infants with low birth weight fell from 16 per 1,000 to 0.3, a 15% drop in total over the same time frame. Between 2005 and 2010 as compared to the 1985–1990 period, infant mortality per 1,000 births also fell from 152 to 109.6. Significantly, maternal mortality per 100,000 births fell from 1,600 in the pre-war 1985–1990 half-decade to 1,100 in the 2000–2005 period. The number of physicians per 100,000 people also rose from 3.4 to 4 over the same time frame, as did the percentage of the population with access to sanitation services, which increased from 18% to 26%. According to United Nations Population Fund data on the midwifery workforce, there is a total of 429 midwives (including nurse-midwives) in Somalia, with a density of one midwife per 1,000 live births. Eight midwifery institutions presently exist in the country, two of which are private. Midwifery is regulated by the government, and a licence is required to practice professionally. A live registry is also in place to keep track of licensed midwives. In addition, midwives in the country are officially represented by a local midwives association, with 350 registered members. According to a 2005 World Health Organization estimate, about 97.9% of Somalia's women and girls underwent female genital mutilation, a pre-marital custom mainly endemic to the Horn of Africa and parts of the Near East.
=== Bernot et al. (2023) === In recent study, Bernot et al. placed Copepoda as a sister group to Branchiopoda in Allotriocarida, which result in the recovery of clade Communostraca. Multicrustacea was not found. There are some major changes within class Malacostraca.
Homoscleromorpha are most closely related to Eumetazoa; calcareous sponges are the next closest; the other demosponges are evolutionary "aunts" of these groups; and the chancelloriids, bag-like animals whose fossils are found in Cambrian rocks, may be sponges. The sperm of Homoscleromorpha share features with the sperm of Eumetazoa, that sperm of other sponges lack. In both Homoscleromorpha and Eumetazoa layers of cells are bound together by attachment to a carpet-like basal membrane composed mainly of "typ IV" collagen, a form of collagen not found in other sponges – although the spongin fibers that reinforce the mesohyl of all demosponges is similar to "type IV" collagen.
Sources: en.wikipedia.org
POMC, ACTH and β-lipotropin are secreted from corticotropic cells in the anterior lobe (or adenohypophysis) of the pituitary gland in response to the hormone corticotropin-releasing hormone (CRH) released by the hypothalamus. The pre-pro-opiomelanocortin (Pre-POMC) is the precursor of POMC, its cleavage forms POMC. ACTH, on the other hand, is produced from the cleavage of POMC. The removal of the signal peptide during translation produces the 241-amino acid polypeptide POMC, which undergoes a series of post-translational modifications such as phosphorylation and glycosylation before it is proteolytically cleaved by endopeptidases to yield various polypeptide fragments with varying physiological activity. These fragments include:
The historicity of the United Monarchy is heavily debated among archaeologists and biblical scholars: biblical maximalists and centrists (Kenneth Kitchen, William G. Dever, Amihai Mazar, Baruch Halpern and others) argue that the biblical account is more or less accurate, while biblical minimalists (Israel Finkelstein, Ze'ev Herzog, Thomas L. Thompson and others) argue that Israel and Judah never split from a singular state. The debate has not been resolved, but recent archaeological discoveries by Eilat Mazar and Yosef Garfinkel show some support for the existence of the United Monarchy. From 850 BCE onwards, a series of inscriptions mention the "House of David". They came from Israel's neighbours.
Gam-COVID-Vac is a viral vector vaccine based on two recombinant replication-defective human adenoviruses: Ad26 (serotype 26) and Ad5 (serotype 5) replicated in HEK 293 cells. The viruses contain the gene that encodes the full-length spike protein (S) of SARS-CoV-2 to stimulate an immune response. Adenoviral vectors for expression of the SARS-CoV-2 spike protein have also been used in two other COVID-19 vaccines. One is the Janssen COVID-19 vaccine, which uses the Ad26COV2 viral vector based on the human virus Ad26. For this vaccine, the cell line PER.C6 is used to replicate the vector. Another one, the Oxford–AstraZeneca COVID‑19 vaccine, uses chimpanzee adenovirus (ChAdOx1) as the vector. For both the Oxford-AstraZeneca COVID-19 and Gam-COVID-Vac vaccines the producer cells for the production of non-replicating adenoviral vectors were obtained from the HEK 293 cell line. Each dose of Gam-COVID-Vac contains (1.0 ± 0.5) × 1011 virus particles. Both Ad26 and Ad5 were modified to remove the E1 gene to prevent replication outside the HEK 293 cells. For the production of the vaccine, to propagate adenoviral vectors in which the E1 gene was deleted, HEK 293 cells are used, which express several adenoviral genes, including E1. However, although rare, homologous recombination between the inserted cellular sequence and the vector sequence can restore the replication capacity to the vector, with less than 100 replicating adenovirus particles per dose of the vaccine.
=== Wet media milling (nanocrystal technology) === In wet media milling, the drug substance is suspended in an aqueous solution containing a stabilizing surfactant or polymer and circulated through a chamber filled with small (typically 0.2–0.5 mm) ceramic, glass, or polymer-coated beads. Bead-on-bead and bead-on-particle impacts progressively reduce the drug particle size to the 100–400 nm range, while the stabilizer adsorbs onto newly created surfaces and prevents agglomeration. The technology, commercialized as NanoCrystal by Elan Drug Technologies (later Alkermes), underpins several U.S. Food and Drug Administration–approved products, including sirolimus (Rapamune oral tablet, approved 2000), aprepitant (Emend, 2003), fenofibrate (Tricor 145 mg, 2004; Triglide, 2005), and megestrol acetate (Megace ES, 2005).
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.